XIENCE V Everolimus Eluting Coronary Stent System (EECSS) USA Post-Approval Study.

Trial Profile

XIENCE V Everolimus Eluting Coronary Stent System (EECSS) USA Post-Approval Study.

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Apr 2016

At a glance

  • Drugs Everolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms XIENCE-V-USA
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 05 Apr 2011 Results presented at the 60th Annual Scientific Session of the American College of Cardiology.
    • 16 Sep 2010 One-year results will be presented at the Cardiovascular Research Foundation's 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, in Washington D.C., according to an Abbott Laboratories media release.
    • 21 May 2010 Results will be presented at EuroPCR 2010 according to an Abbott media release. Data will include one-year primary endpoint data on blood clots (stent thrombosis) and dual antiplatelet usage.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top